[go: up one dir, main page]

MX366425B - Nuevos polipeptidos. - Google Patents

Nuevos polipeptidos.

Info

Publication number
MX366425B
MX366425B MX2015012215A MX2015012215A MX366425B MX 366425 B MX366425 B MX 366425B MX 2015012215 A MX2015012215 A MX 2015012215A MX 2015012215 A MX2015012215 A MX 2015012215A MX 366425 B MX366425 B MX 366425B
Authority
MX
Mexico
Prior art keywords
fcrn
present disclosure
binding polypeptide
new polypeptides
relates
Prior art date
Application number
MX2015012215A
Other languages
English (en)
Other versions
MX2015012215A (es
Inventor
Ekblad Caroline
Abrahmsén Lars
Lindborg Malin
Gunneriusson Elin
Löfblom John
Gräslund Torbjörn
Seijsing Johan
Original Assignee
Affibody Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affibody Ab filed Critical Affibody Ab
Publication of MX2015012215A publication Critical patent/MX2015012215A/es
Publication of MX366425B publication Critical patent/MX366425B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)

Abstract

La presente exposición se refiere a una clase de polipéptidos diseñados que tienen una actividad de enlace para el receptor neonatal Fc (en lo siguiente referido como FcRn) y proporciona un polipéptido de enlace a FcRn que comprende la secuencia EX2 X3 X4 AX6 X7 EIRWLPNL X16X17 X18 QRX21 AFIX25 X26LX28 X29. La presente exposición se refiere también al uso de tal polipéptido de enlace a FcRn como un agente para modificar las propiedades farmacocinéticas y farmacodinámicas y como un agente terapéutico.
MX2015012215A 2013-03-15 2014-03-17 Nuevos polipeptidos. MX366425B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361787305P 2013-03-15 2013-03-15
EP13159500 2013-03-15
PCT/EP2014/055299 WO2014140366A1 (en) 2013-03-15 2014-03-17 New polypeptides

Publications (2)

Publication Number Publication Date
MX2015012215A MX2015012215A (es) 2016-05-16
MX366425B true MX366425B (es) 2019-07-04

Family

ID=47891491

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012215A MX366425B (es) 2013-03-15 2014-03-17 Nuevos polipeptidos.

Country Status (16)

Country Link
US (3) US9975943B2 (es)
EP (1) EP2970406B1 (es)
JP (1) JP6608288B2 (es)
KR (1) KR102191654B1 (es)
CN (1) CN105209482B (es)
AU (1) AU2014230018B2 (es)
BR (1) BR112015021730A2 (es)
CA (1) CA2902657C (es)
DK (1) DK2970406T3 (es)
ES (1) ES2660912T3 (es)
IL (1) IL240606B (es)
LT (1) LT2970406T (es)
MX (1) MX366425B (es)
MY (1) MY171407A (es)
RU (1) RU2681428C2 (es)
WO (1) WO2014140366A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2679681B2 (en) 2011-02-25 2023-11-15 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific FC antibody
EP4011913A1 (en) 2011-06-30 2022-06-15 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
CN104080909A (zh) 2011-11-30 2014-10-01 中外制药株式会社 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物
RS58503B1 (sr) 2012-02-20 2019-04-30 Swedish Orphan Biovitrum Ab Publ Polipeptidi koji se vezuju za humani komplement c5
JP6501521B2 (ja) 2012-08-24 2019-04-17 中外製薬株式会社 ＦｃγＲＩＩｂ特異的Ｆｃ領域改変体
KR102249779B1 (ko) 2012-12-27 2021-05-07 추가이 세이야쿠 가부시키가이샤 헤테로이량화 폴리펩티드
US9975943B2 (en) 2013-03-15 2018-05-22 Affibody Ab Polypeptides
ZA201506407B (en) * 2013-03-15 2018-11-28 Affibody Ab New polypeptides
CA2908350C (en) 2013-04-02 2023-08-08 Futa Mimoto Fc region variant
SI3193930T1 (sl) 2014-09-17 2019-10-30 Affibody Ab Novi polipeptidi
MY181199A (en) 2014-12-19 2020-12-21 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
PL3245224T3 (pl) * 2015-01-12 2021-01-25 Affibody Ab Polipeptydy wiążące il-17a
CN107108729A (zh) 2015-02-05 2017-08-29 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il‑8‑结合抗体，及其应用
US11155596B2 (en) * 2015-10-30 2021-10-26 Affibody Ab Polypeptide
EP3368557A1 (en) 2015-10-30 2018-09-05 Affibody AB New polypeptide
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
JP6527643B2 (ja) 2016-08-05 2019-06-05 中外製薬株式会社 Ｉｌ−８関連疾患の治療用又は予防用組成物
UY37651A (es) * 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i
EP3710589A4 (en) 2017-11-14 2021-11-10 Chugai Seiyaku Kabushiki Kaisha ANTI-C1S ANTIBODIES AND METHOD OF USING
JP7422659B2 (ja) 2017-12-08 2024-01-26 アルジェニクス ビーブイ 全身型重症筋無力症治療のためのＦｃＲｎアンタゴニストの使用
MX2020013195A (es) 2018-06-08 2021-02-26 Argenx Bvba Composiciones y metodos para el tratamiento de la trombocitopenia inmunitaria.
SG10202106830VA (en) 2018-08-10 2021-08-30 Chugai Pharmaceutical Co Ltd Anti-cd137 antigen-binding molecule and utilization thereof
US12274759B2 (en) 2018-08-23 2025-04-15 Regents Of The University Of Minnesota Affibody proteins specific for B7-H3 (CD276)
CA3137649A1 (en) 2019-05-15 2020-11-19 Chugai Seiyaku Kabushiki Kaisha An antigen-binding molecule, a pharmaceutical composition, and a method
WO2021089695A1 (en) * 2019-11-05 2021-05-14 Affibody Ab Polypeptides
FI4087875T3 (fi) 2020-01-08 2024-10-25 argenx BV Vastasyntyneen ihmisen Fc-reseptorin (FcRn) antagonisteja pemfigus-häiriöiden hoitoon
KR20240135659A (ko) * 2022-01-24 2024-09-11 리젠츠 오브 더 유니버시티 오브 미네소타 항-b7-h3 화합물 및 사용 방법
WO2023242372A1 (en) 2022-06-15 2023-12-21 argenx BV Fcrn/hsa binding molecules and methods of use
TW202428303A (zh) * 2022-11-07 2024-07-16 比利時商阿根思公司 使用ｆｃｒｎ拮抗劑治療原發性膜性腎病變之方法
WO2025073871A1 (en) 2023-10-03 2025-04-10 Bicycletx Limited Bicyclic peptide ligand complexes specific for tfr1
CN119409765A (zh) * 2024-10-31 2025-02-11 中山大学 一种FcRn亲和母体肽、衍生肽及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602977B1 (en) * 1999-04-19 2003-08-05 Biovitrum Ab Receptor structures
US20100266530A1 (en) 2005-04-29 2010-10-21 The Jackson Laboratory FcRN ANTIBODIES AND USES THEREOF
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
CN101421297A (zh) * 2006-02-17 2009-04-29 森托尼克斯制药有限公司 阻断lgG对FcRn的结合的肽
US8937153B2 (en) 2007-07-31 2015-01-20 Affibody Ab Compositions, methods and uses
MX2010001363A (es) * 2007-08-09 2010-03-09 Syntonix Pharmaceuticals Inc Peptidos inmunomoduladores.
DK2231860T3 (da) 2007-12-19 2011-12-05 Affibody Ab Polypeptid afledt protein A og i stand til at binde PDGF
BRPI0910622A2 (pt) 2008-04-25 2020-03-10 Dyax Corp. ANTICORPOS CONTRA FcRn E USOS DOS MESMOS
WO2010054699A1 (en) 2008-11-17 2010-05-20 Affibody Ab Conjugates of albumin binding domain
JP5960598B2 (ja) 2009-11-04 2016-08-02 アフィボディ・アーベー Ｈｅｒ３結合ポリペプチド
WO2012004384A2 (en) * 2010-07-09 2012-01-12 Affibody Ab Polypeptides
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
JP2014510518A (ja) * 2011-02-15 2014-05-01 メディミューン，エルエルシー Ｈｓａ関連組成物および使用方法
JP6382826B2 (ja) 2012-10-25 2018-08-29 アフィボディ・アーベー アルブミン結合ポリペプチド
US9975943B2 (en) 2013-03-15 2018-05-22 Affibody Ab Polypeptides
MX367423B (es) 2013-08-28 2019-08-21 Affibody Ab Polipeptidos de union a c5.
SI3193930T1 (sl) 2014-09-17 2019-10-30 Affibody Ab Novi polipeptidi

Also Published As

Publication number Publication date
CN105209482A (zh) 2015-12-30
AU2014230018B2 (en) 2018-02-22
MY171407A (en) 2019-10-11
IL240606B (en) 2020-05-31
WO2014140366A1 (en) 2014-09-18
HK1216756A1 (en) 2016-12-02
US20160031967A1 (en) 2016-02-04
JP6608288B2 (ja) 2019-11-20
CA2902657C (en) 2022-05-10
US20180118807A1 (en) 2018-05-03
CN105209482B (zh) 2022-04-29
CA2902657A1 (en) 2014-09-18
EP2970406A1 (en) 2016-01-20
US10562955B2 (en) 2020-02-18
MX2015012215A (es) 2016-05-16
RU2015141224A (ru) 2017-04-21
DK2970406T3 (en) 2018-02-05
RU2681428C2 (ru) 2019-03-06
AU2014230018A1 (en) 2015-11-05
US9975943B2 (en) 2018-05-22
LT2970406T (lt) 2018-03-12
IL240606A0 (en) 2015-09-24
ES2660912T3 (es) 2018-03-26
JP2016511280A (ja) 2016-04-14
KR20150132349A (ko) 2015-11-25
US20200199197A1 (en) 2020-06-25
BR112015021730A2 (pt) 2017-08-29
KR102191654B1 (ko) 2020-12-16
EP2970406B1 (en) 2017-12-13

Similar Documents

Publication Publication Date Title
MY171407A (en) New polypeptides
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
WO2015063611A3 (en) Albumin variants and uses thereof
SI3265478T1 (sl) Fuzijski proteini, ki obsegajo vezavni protein in polipeptid interlevkin-15, ki ima zmanjšano afiniteto za IL15RA, in terapevtske uporabe le-teh
WO2015007536A3 (en) Fusokines involving cytokines with strongly reduced receptor binding affinities
ZA201604464B (en) Fcrn antagonists and methods of use
MX2017003459A (es) Polipeptidos novedosos.
WO2013184939A3 (en) Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
PH12014502767A1 (en) Interleukin-2 fusion proteins and uses thereof
IL243568B (en) Conjugation of a biologically active polypeptide monomer and an immunoglobulin fragment fc with a reduction in receptor elimination and a method for its preparation
WO2013177398A3 (en) Non-natural consensus albumin binding domains
MX2015011350A (es) Proteinas de fusion de apelina y usos de estas.
MY188784A (en) Il-17a-binding polypeptides
PH12016500111A1 (en) An immunoglobulin fc conjugate which maintains binding affinity of immunoglobulin fc fragment to fcrn
HK1220619A1 (zh) 因子ix多肽调配物
SG11201508900UA (en) Alternative formulations for tnfr: fc fusion polypeptides
SG11201706543UA (en) Fc Fusion High Affinity IgE Receptor α-Chain
EP2969009A4 (en) MODIFIED FC FUSION PROTEINS
IL273368A (en) Composite medical preparations with increased binding capacity to albumin
EP3059313A4 (en) Recombinant peptide vaccines against ticks, and nucleotide sequences coding for the recombinant peptides
TH148778A (th) เปปไทด์รักษาโรค

Legal Events

Date Code Title Description
FG Grant or registration